Mangalam Drugs & Organics (NSE:MANGALAM) Cyclically Adjusted Revenue per Share: ₹253.96 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:MANGALAM Mangalam Drugs & Organics Ltd NSE:MANGALAM
47 GF Score
Price ₹31.98
GF Value ₹61.67
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is Mangalam Drugs & Organics Cyclically Adjusted Revenue per Share?

Mangalam Drugs & Organics NSE:MANGALAM -4.65% 47 Cyclically Adjusted Revenue per Share is ₹253.96 as of Jun. 2026. GuruFocus rates NSE:MANGALAM with a GF Score™ of 47/100 and a GF Value™ of ₹61.67 (Possible Value Trap). The stock has 3 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Mangalam Drugs & Organics's adjusted revenue per share for the three months ended in Jun. 2026 was ₹36.087. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is ₹253.96 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Mangalam Drugs & Organics's average Cyclically Adjusted Revenue Growth Rate was -0.90% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 1.80% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 4.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Mangalam Drugs & Organics was 8.40% per year. The lowest was 1.80% per year. And the median was 5.50% per year.

As of today (2026-09-17), Mangalam Drugs & Organics's current stock price is ₹31.98. Mangalam Drugs & Organics's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was ₹253.96. Mangalam Drugs & Organics's Cyclically Adjusted PS Ratio of today is 0.13.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Mangalam Drugs & Organics was 0.90. The lowest was 0.09. And the median was 0.45.


Mangalam Drugs & Organics  (NSE:MANGALAM) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Mangalam Drugs & Organics's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=31.98/253.961
=0.13

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Mangalam Drugs & Organics was 0.90. The lowest was 0.09. And the median was 0.45.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Mangalam Drugs & Organics Cyclically Adjusted Revenue per Share Related Terms


Mangalam Drugs & Organics Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Mangalam Drugs & Organics's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Mangalam Drugs & Organics Cyclically Adjusted Revenue per Share Chart

Mangalam Drugs & Organics Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 215.22 234.87 252.32 253.53 249.04

Mangalam Drugs & Organics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 258.20 256.65 253.65 252.30 253.96

NSE:MANGALAM vs ZTS: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Mangalam Drugs & Organics's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Mangalam Drugs & Organics Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Mangalam Drugs & Organics's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Mangalam Drugs & Organics's Cyclically Adjusted PS Ratio falls into.


NSE:MANGALAM
47GF Score
Mangalam Drugs & Organics Ltd NSE:MANGALAM
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Mangalam Drugs & Organics Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Mangalam Drugs & Organics's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=36.087/167.3573*167.3573
=36.087

Current CPI (Jun. 2026) = 167.3573.

Mangalam Drugs & Organics Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 48.081 105.961 75.940
201612 50.871 105.196 80.931
201703 52.380 105.196 83.332
201706 34.834 107.109 54.428
201709 52.527 109.021 80.633
201712 46.693 109.404 71.427
201803 42.453 109.786 64.715
201806 37.280 111.317 56.048
201809 45.426 115.142 66.026
201812 30.694 115.142 44.613
201903 30.382 118.202 43.017
201906 41.093 120.880 56.893
201909 42.502 123.175 57.747
201912 39.135 126.235 51.883
202003 55.657 124.705 74.693
202006 65.478 127.000 86.285
202009 61.299 130.118 78.843
202012 56.031 130.889 71.642
202103 57.358 131.771 72.848
202106 66.197 134.084 82.624
202109 72.151 135.847 88.887
202112 64.365 138.161 77.967
202203 75.706 138.822 91.268
202206 68.043 142.347 79.998
202209 67.201 144.661 77.744
202212 40.009 145.763 45.936
202303 57.560 146.865 65.592
202306 55.261 150.280 61.541
202309 51.525 151.492 56.921
202312 61.495 152.924 67.299
202403 64.590 153.035 70.635
202406 48.354 155.789 51.945
202409 50.507 157.882 53.538
202412 56.047 158.323 59.245
202503 46.144 157.552 49.016
202506 36.232 159.755 37.956
202509 31.301 162.289 32.278
202512 36.951 163.281 37.874
202603 42.511 164.272 43.309
202606 36.087 167.357 36.087

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of ₹253.96 mean?
Mangalam Drugs & Organics (NSE:MANGALAM) has a Cyclically Adjusted Revenue per Share of ₹253.96 as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Mangalam Drugs & Organics and its competitors.
Is Mangalam Drugs & Organics' Cyclically Adjusted Revenue per Share too high?
Mangalam Drugs & Organics' current Cyclically Adjusted Revenue per Share is ₹253.96. Overall, Mangalam Drugs & Organics has a GF Score™ of 47/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Mangalam Drugs & Organics' Cyclically Adjusted Revenue per Share compare to ZTS?
Mangalam Drugs & Organics' Cyclically Adjusted Revenue per Share of ₹253.96 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Mangalam Drugs & Organics and its competitors. Mangalam Drugs & Organics's current Cyclically Adjusted Revenue per Share is ₹253.96. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mangalam Drugs & Organics stock overvalued right now?
Based on GuruFocus' analysis, Mangalam Drugs & Organics (NSE:MANGALAM) is currently considered Possible Value Trap. The stock's GF Value™ is ₹61.67, compared to a current price of ₹31.98 — trading 48.1% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is ₹253.96. Mangalam Drugs & Organics' overall GF Score™ is 47/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Mangalam Drugs & Organics (NSE:MANGALAM), the current Cyclically Adjusted Revenue per Share is ₹253.96 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Mangalam Drugs & Organics (NSE:MANGALAM) Overvalued in 2026?

Based on GuruFocus' analysis, Mangalam Drugs & Organics stock appears to be undervalued. The current stock price of ₹31.98 is trading 48.1% below its estimated GF Value™ of ₹61.67. GuruFocus considers Mangalam Drugs & Organics to be Possible Value Trap.

Key valuation signals for NSE:MANGALAM:

  • Cyclically Adjusted Revenue per Share: ₹253.96
  • GF Value™: ₹61.67 vs. price of ₹31.98 (48.1% below fair value)
  • GF Score™: 47/100 with 3 warning signs

No single metric tells the full story. See the NSE:MANGALAM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Mangalam Drugs & Organics Business Description

Other Exchanges 532637:India
Address P. D'Mello Road, Rupam Building, 3rd Floor, No. 239, Near General Post Office, Mumbai, MH, IND, 400001
Mangalam Drugs & Organics Ltd commenced its manufacturing of Active Pharmaceutical Ingredients (APIs) and intermediates. The company is engaged in the manufacture and sale of APIs for various therapeutic segments, including anti-malaria, anti-retroviral, and anti-hypertensive. It is approved by the Bill Clinton Foundation. The company is actively producing Pyronaridine Tetraphosphate, a new API used in antimalarial treatments. The company has received prequalification from the World Health Organization (WHO) for both micronized and non-micronized forms of Pyronaridine Phosphate.
47GF Score

Get the complete analysis for NSE:MANGALAM

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹31.98
Price
₹61.67
GF Value